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To study the antigens involved in the islet cell
antibody (ICA) reaction we selected 30 patient
serum samples (ten in each group) positive for ICA
and one other additional autoantibody, such as
glutamic acid decarboxylase antibodies (GADA),
thyrosine phosphatase antibodies (IA-2A) or insulin
autoantibodies (IAA). The serum samples were
incubated with the specific antigen (GAD65, IA-2 or
insulin) and the ICA analysis and the corresponding
immunoprecipitation assay were performed before
and after the absorption.
We could then demonstrate that specific autoanti-
bodies against GAD65 and IA-2 could be absorbed
with the corresponding antigen, since ten GADA
positive and six IA-2A samples turned completely
negative. However, the ICA reaction after absorption
with GADA, IA-2A and insulin was still present,
although at significantly lower levels. The results
strongly indicate that the ICA reaction represents
simultaneous autoimmunity against several other
antigens beside GAD65, IA-2 and insulin.
Keywords: Diabetes mellitus; Autoantibodies; Islet cell
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INTRODUCTION
Type 1 diabetes has been regarded as an
autoimmune disease since islet cell antibodies
(ICA) were described in diabetic patients in
1974. [1] The immunofluorescense method for
ICA do not define the antigen and the search for
the antigen responsible for this reaction started.
Insulin was one strong candidate and autoan-
tibodies against insulin were later also demon-
strated in Type 1 diabetic patients. [21 Insulin
autoantibodies (IAA) were soon followed by the
discovery of several other autoantibodies.TM
Glutamic acid decarboxylase antibodies
(GADA) [4] and thyrosine phosphataseantibodies
(IA-2A) [5,6] are two of the most frequently
occuring autoantibodies together with IAA.
Beside pure proteins like GAD65, IA-2 and others,
a sialic acid containing glycolipid [7] has been
shown to be another antigen in autoimmune
diabetes. However, it has been suggested that
most of ICA’s reactivity is represented by
GADA [8] and IA-2A. [5,9]
From a large population based study, [1] we
had the possibility to select groups of samples
with a combination of ICA positivity together
with an isolated positivity for either GADA, IA-
2A or IAA. The aim was to study to which
extent the ICA reaction could be blocked by an
absorption to the specific antigen (GAD65, IA-2
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or insulin). This would clarify if GAD65, IA-2
and insulin respectively were the main antigens
that contribute to the ICA reaction or if other
antigens have to be taken into account.
MATERIALS AND METHODS
Materials
Samples were selected from The Diabetes
Incidence Study in Sweden (DISS), a nation-
wide study including 764 newly diagnosed
diabetic patients in the ages 15-34 years. [11 We
selected 30 samples, all positive for ICA and in
addition positive for one more autoantibody
(GADA, IA-2A or IAA). In the first group in
which positivity for ICA and GADA was
required, 61 samples fulfilled the criteria and ten
were randomly selected. In the ICA and IA-2A
positive group, 26 samples were available and
ten were randomly selected. In the third group,
only three samples were exclusively positive for
only ICA and IAA, and a weak GADA positivity
was therefore allowed in the remaining seven
samples. The study was approved by the Ethical
Committees at all University Hospitals in
Sweden (Stockholm, G6teborg, Link6ping,
Lund, Umeg and Uppsala).
Assays
ICA were analysed by indirect immunofluo-
rescence on unfixed human pan-creas from an
organ donor with bloodgroup 0 [11]. Levels were
expressed as Juvenile Diabetes Foundation Units
(JDF-U) and the lower limit for positivity was 4
JDF-U. All analyses were performed in a blinded
format.
GADA were analysed in a radioimmunopre-
cipitation assay using in vitro translated human
GAD65 labelled with 35S-methionine.[12] Levels
were expressed as an index calculated in relation
to a positive and negative standard sample. An
index below 0.08 was considered as negative.
IA-2A were analysed in a radioimmunopre-
cipitation assay similar to the GADA-assay.[13]
An index below 0.05 was considered as negative.
IAA were analysed by radioimmunoassay
and the samples were also displaced by cold
insulin to avoid unspecific binding. [21 A specific
A-binding percent below 0.8 was considered as
negative.
Preparation of Antigens
GAD65 and IA-2 were prepared using the TNT(R)
Coupled Reticulocyte Lysate System (Promega,
Madison, USA) for in vitro transcription-
translation. [12,13] An approximation of the
obtained protein concentration was done by
using the Luciferase Assay System (Promega,
Madison, USA). A standard curve of light units
versus enzyme concentration was produced
with a luminometer giving an indirect measure-
ment of the protein concentration. From
previous performed ELISA assays of GADA, we
could approximate that an amount of 40-180 ng
cold antigen for each millilitre of test serum
would be needed to bind the autoantibodies.
Since insulin in the form of the commercial
insulin Actrapid
(R) (Novo Nordisk, Denmark),
was contrary to GAD65 and IA-2, available in
unlimited amounts it was added in excess
(3.5mg/ml) to the IAA positive samples. One
samples was reanalysed after absorption with
half insulin and half serum.
Absorption
Each serum sample was divided in two
aliquotes, one was incubated with the cold
antigen, as described above, for 12 hours at
4C, and the other was used as a control. Both
aliquotes were equally diluted and reanalysed
for ICA and for the specific antibody (GADA
or IA-2A) by the immunoprecipitation assay.
Since cold insulin was available in unlimited
amounts and therefore added in excess, the
IAA positive samples were only reanalysed for
INTERNATIONAL JOURNAL OF EXPERIMENTAL DIABETES RESEARCHAUTOANT IGENS FOR ICA 87
ICA but not for IAA. To test if immunoreactive
insulin was available in the tissue samples, a
pancreas section was incubated with an anti-
insulin antibody from mouse (mouse anti-
human insulin IgG, Santa Cruz Biotechnology,
USA). In this experiment immunoreactive
insulin was detected by a Texas red labelled
anti-mouse IgG.
Due to dilutions during the absorption pro-
cedure, ICA levels below 29 JDF units could
not be determined after absorption. To test the
absorption procedure as such, some samples
were retested after incubation with bovine
serum albumin (BSA) as an irrelevant antigen.
Statistical Analyses
The Spearman rank correlation test (rs) was
used to test for correlations between ICA and
the other antibodies. Levels of autoantibodies
before and after absorption were compared
with Wilcoxon signed rank test. A p-value less
than 0.05 was considered as significant. Stat
View 4.5 for Macintosh was used.
RESULTS
Among these highly selected samples, no
significant correlation could be found between
ICA and the other antibodies, GADA, IA-2A or
IAA. In the group of ICA and GADA positive
samples, GADA could be absorbed since the
levels were significantly lower (p < 0.005), and
all samples were considered GADA negative
after absorption with GAD65. Of these samples,
eight of ten showed a reduction in ICA level (p
0.01), corresponding to one or two dilution steps
(Fig. 1). However, eight of the ten samples were
still ICA positive, and the remaining two had a
level below 29 JDF units but exact ICA level
could not be determined, due to prior dilution
during the absorption procedure. Anyhow, both
these were at least two dilution steps lower than
before absorption. In the group positive for ICA
and IA-2A, four samples were still weakly IA-2A
positive after absorption with IA-2, while IA-2A
were abolished in the others. The decreases in
levels were significant (p 0.005). Nine of ten















FIGURE 1 In the group with ten samples positive for ICA and GADA the initially positive GADA levels totally disappeared
after absorption with cold GAD65 (a). Index below 0.08 was considered as negative and indicated by a dashed line.
Corresponding analyses for ICA showed a significant but not complete decrease in ICA levels after absorption with GAD65 (b).
For two of the samples, the lowest JDF-U was not possible to determine due to dilution during the absorption procedure. The
cut off level of 4 JDF-U is indicated with a dashed line.













(a) Before After (b) Before After
FIGURE 2 In the group positive for ICA and IA-2A, a remaining weak IA-2A positivity could be demonstrated in four of the
ten samples despite absorption with IA-2 (a). Index below 0.05 was considered as negative and is indicated by a dashed line.
Decreased ICA levels were found after absorption with IA-2 (b). For two of the samples, the lowest JDF-U was not possible to








FIGURE 3 In the ICA and IAA positive group, seven of ten
samples showed a decrease in ICA level. The cut off level 4
JDF-U is shown by the dashed line.
or two ICA titer steps (p 0.01) (Fig. 2), although
the lowest ICA levels not could be determined
in two samples due to prior dilutions. None of
the eight end point titrated samples turned
completely negative for ICA. In the ICA and IAA
positive group, seven of ten showed a decrease
in ICA level (p 0.005) after insulin absorption,
but none became totally ICA negative (Fig. 3).
One of the samples positive for ICA and IAAwas
reanalysed after insulin added in dilution half
insulin and half serum, despite this the ICA
reaction was still positive. The pancreas section
incubated with an anti-insulin antibody turned
out with a positive immunofluorescence,
confirming that immunoreactive insulin was
available in the tissue sections. The sample
incubated with BSA, an irrelevant antigen, did
not change the levels ofGADA or ICA.
DISCUSSION
The study showed that ICA were not easily
abolished by a single absorption with one
specific antigen, even if the antigen specific
antibody disappeared. This finding indicate that
several autoantibodies others than GADA, IA-
2A and IAA are simultaneously present in Type
1 diabetes, even if there is a dominance of one
of these autoantibodies. Many studies suggest
that GAD65, IA-2 and insulin are the major
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antigens responsible for the ICA reaction. [8,91
Since ICA is such a time consuming and in many
aspects complicated assay, a combination of the
immunoprecipitation analyses for GADA and
IA-2A have been suggested to replace the ICA
method. [14,15] Our results indicate that several
other antigens not tested in this study, are
involved in the ICA reaction.
Correlations between ICA levels and levels of
GADA and IA-2A have been demonstrated in
the entire cohort from which we did the original
selection. [1] However, in this subset of samples
no correlation could be found between ICA and
the other autoantibodies (GADA, IA-2A or
insulin). This could be due to the small number
of samples and to the fact that they were highly
selected.
In this study we could show an almost
complete block of GADA and IA-2A after
absorption with the corresponding specific
antigen, GAD65 and IA-2. However, in four of
ten IA-2A positive samples, IA-2A could still be
detected after absorption but in very low levels.
This could be due to an incubation with
insufficient amount of antigen, since all four
samples had relatively high initial level of
IA-2A, the amount of antigen was limited and
the needed amount for absorption could only be
approximised. However, against this could be
argued that the sample positive for ICA and IAA
that was reanalysed with insulin in excess was
still ICA positive.
The specific autoantibodies are not evenly
represented among the diabetic population,
since for example GADA is more frequent in
females and in higher ages, while IAA are
more frequent in young children. [16] ICA seems
to be more evenly distributed among type 1
diabetic patients, despite a higher frequency
among children compared with adults, [171
probably reflecting the general autoimmunity
among these patients rather than gender or age
specificity for the antibody. Our hypothesis is
that different exogenous triggers, depending
on different environmental factors related
to age, gender and life exposure, could start
an immune response. This could, in suscep-
tible subjects, lead to a general activation
and hyperreactivity against an increasing
number of beta cell specific autoantigens. The
autoimmune response could also spread
outside the beta cells since in fact other
autoimmune diseases are more frequent
among diabetic patients. [181 In others, the
initial immune response may be self limiting
and never proceed to clinical signs of diabetes.
This is supported by the observed low
predictability of diabetes in healthy subjects
positive for only one autoantibody and the
increasing risk for diabetes with multiple
autoantibody positivity. [19]
In conclusion, both GADA, IA-2A and IAA
are partly responsible for the ICA reaction in
sera from patients positive for ICA. However,
if ICA’s reactivity was constituted only of
these autoantibodies the ICA reaction would be
blocked more completely than what was found
in our study. Our results indicate a more
extended heterogeneity of the contribution
to ICA positivity and probably simultaneous
involvement of several other beta cell specific
autoantigens beside GAD65, IA-2 and insulin.
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